Compare FIRY & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIRY | HURA |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.8M | 160.5M |
| IPO Year | 2020 | 2010 |
| Metric | FIRY | HURA |
|---|---|---|
| Price | $11.56 | $1.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 117.3K | ★ 250.0K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | N/A |
| Revenue This Year | $22.11 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $0.41 |
| 52 Week High | $14.12 | $3.43 |
| Indicator | FIRY | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 51.91 |
| Support Level | $9.31 | $1.83 |
| Resistance Level | $14.02 | $2.22 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 49.35 | 57.14 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.